Treatment endpoints for chronic hepatitis D.
- Resource Type
- Academic Journal
- Authors
- Metin O; Department of Gastroenterology, Prof. Cemil Taşçioğlu City Hospital, Istanbul, Turkey.; Zeybel M; Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey.; Yurdaydin C; Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey.
- Source
- Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101160857 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-3231 (Electronic) Linking ISSN: 14783223 NLM ISO Abbreviation: Liver Int Subsets: MEDLINE
- Subject
- Language
- English
Management of chronic hepatitis D (CHD) has entered a new era. In this new era, the virus entry inhibitor bulevirtide has received conditional approval as a treatment for compensated CHD. Three phase 3 studies with two new compounds are ongoing for the treatment of CHD. In this context, surrogate markers of treatment efficacy have been well defined for chronic hepatitis B (CHB) (7) and chronic hepatitis C (8) but not for CHD. The aim of this review is to give a perspective on treatment endpoints in CHD. For this, we took guidance from CHB studies and tried to make suggestions which differed according to finite versus prolonged treatment durations and also took into account the different characteristics of the new compounds.
(© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)